Floatz logo

Olaparib

DLBCL

Acerta Pharma BVSmall moleculePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

19 Active assets in the DLBCL cohort.

Asset / SponsorPhaseRating
Selinexor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Ruijin Hospital
Phase 3BB
Pyrotinib
Seoul National University Hospital
Phase 2BB
rc48-adc
Seoul National University Hospital
Phase 2BB
Vistusertib
Acerta Pharma BV
Phase 2B

View all 37 →

Same molecule, other indications

Olaparib is also rated in:

breast carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
fallopian tube serous adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →